

CORGENIX MEDICAL CORP/CO

Form 4

March 11, 2015

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
LUDVIGSON DAVID

2. Issuer Name **and** Ticker or Trading  
Symbol  
CORGENIX MEDICAL CORP/CO  
[CONX]

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

(Last) (First) (Middle)  
11575 MAIN STREET, SUITE 400  
(Street)

3. Date of Earliest Transaction  
(Month/Day/Year)  
03/10/2015

☒ Director ☐ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

BROOMFIELD, CO 80020

4. If Amendment, Date Original  
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V Amount (D) Price			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form  
displays a currently valid OMB control  
number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)

# Edgar Filing: CORGENIX MEDICAL CORP/CO - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
"Right to buy" common stock options	\$ 0.215	03/10/2015	D		40,000		08/27/2013	08/27/2020	Common Stock	40,000
"Right to buy" common stock options	\$ 0.1	03/10/2015	D		40,000		08/27/2012	08/27/2019	Common Stock	40,000
"Right to buy" common stock options	\$ 0.085	03/10/2015	D		40,000		08/29/2011	08/29/2018	Common Stock	40,000
"Right to buy" common stock options	\$ 0.107	03/10/2015	D		40,000		09/28/2010	09/28/2017	Common Stock	40,000

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
LUDVIGSON DAVID 11575 MAIN STREET, SUITE 400 BROOMFIELD, CO 80020		X		

## Signatures

/s/ David  
Ludvigson  
03/11/2015

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: CORGENIX MEDICAL CORP/CO - Form 4

This option, which has vested in full, was cancelled, pursuant to that certain Agreement and Plan of Merger, dated as of August 27, 2014, by and among Corgenix Medical Corp ("Corgenix"), Centennial Medical Holdings, Inc. ("Centennial") and Centennial Integrated, Inc., a

- (1) wholly owned subsidiary of Centennial, pursuant to which Corgenix has been acquired by Centennial (the "Merger"), in exchange for a cash payment of \$2,200, representing (a) the number of shares underlying the option, multiplied by (b) the excess of \$0.27 over the exercise price per share of the option (the "Option Merger Consideration").
- (2) This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of \$6,800, representing the Option Merger Consideration.
- (3) This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of \$7,400, representing the Option Merger Consideration.
- (4) This option, which has vested in full, was cancelled in the Merger in exchange for a cash payment of \$6,520, representing the Option Merger Consideration.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.